Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 910, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174486
Keywords
Ipragliflozin; Hyperglycemia; Urinary glucose excretion; Blood glucose-dependent; Diabetes
Categories
Funding
- Astellas Pharma Inc.
Ask authors/readers for more resources
Ipragliflozin, an SGLT2 inhibitor, demonstrates significant antihyperglycemic effects and increases urinary glucose excretion in a hyperglycemic state, but has weaker effects in non-hyperglycemic or hypoglycemic conditions. These effects are dependent on blood glucose levels.
This study investigated the antihyperglycemic effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin via the blood glucose-dependent increase in urinary glucose excretion in KK/Ay type 2 diabetic mice. In oral glucose tolerance tests (glucose load: 1, 2, or 4 g/kg) in 24-h-fasted mice, blood glucose levels increased in a glucose-loading dose-dependent manner. Oral administration of ipragliflozin (1 mg/kg) significantly inhibited the increase in blood glucose concomitant with urinary glucose excretion. To investigate the effects of ipragliflozin under low blood glucose conditions, blood glucose level and urinary glucose excretion were examined under fasting conditions in diabetic mice that had prefasted for 0, 6, 12, 18, or 24 h. Ipragliflozin significantly lowered blood glucose levels in mice that had prefasted for 0, 6, or 12 h, but not 18 h or more. Blood glucose level was well correlated with ipragliflozin-induced antihyperglycemic and urinary glucose excretion effects, suggesting that these effects occur in a blood glucose-dependent manner. Thus, in a hyperglycemic state, ipragliflozin exerts a potent antihyperglycemic effect and marked increases in urinary glucose excretion; however, in a non-hyperglycemic or hypoglycemic state, the hypoglycemic effect is weak. Ipragliflozin may therefore be a useful antidiabetic agent for normalizing daily blood glucose fluctuations in type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available